Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who are able to carry out normal daily activities with little to no limitation from their illness (confirmed by a standardised medical assessment called ECOG, scoring 0 or 1)
• People with a confirmed diagnosis of Stage III non-small-cell lung cancer (NSCLC) — either squamous or non-squamous type — that has been assessed by the investigator as unable to be surgically removed
• People whose tumour, if it contains a mix of cancer types, is classified as either squamous or non-squamous based on the main component present
• People whose cancer meets specific criteria for being considered inoperable, such as spread to certain lymph nodes, invasion of major organs or blood vessels, extensive chest wall involvement, particular tumour locations, or physical inability to tolerate lung surgery
• People who have at least one tumour that can be measured using standard imaging criteria (RECIST v1.1)
• People whose blood counts, kidney function, liver function, and heart function meet specific levels required by the trial (tested within 14 days before starting treatment, without recent use of blood products or growth factor medications)
• Women who are able to become pregnant must have a negative pregnancy test within 72 hours before joining, must not be breastfeeding, and must agree to use effective contraception during the study and for at least 3 months after treatment ends
• Men with female partners who could become pregnant must agree to use effective contraception during the study and for 3 months after the last dose of the study drug
• People who have read and signed the informed consent form agreeing to take part

Who may not be able to join:

• People whose NSCLC has specific gene changes (such as EGFR active mutations, ALK rearrangements, or other driver mutations) for which an approved targeted therapy already exists
• People who have had or currently have another cancer within the past five years, with some exceptions such as certain treated skin cancers, early-stage cervical cancer, localised prostate cancer after surgery, or other cancers the investigator considers fully treated
• People whose tumour contains any small-cell lung cancer component (confirmed by tissue testing)
• People who have already received any systemic (whole-body) cancer treatment
• People with significant heart or blood vessel problems, including a heart attack or unstable chest pain in the past 6 months, a stroke or mini-stroke in the past 6 months, high blood pressure that cannot be controlled with treatment, moderate-to-severe heart failure, or inflammation of the heart muscle
• People who have taken steroid tablets or injections (such as prednisone at more than 10 mg per day) or other immune-suppressing medications within 2 weeks before starting the trial (inhaled or skin-applied steroids and hormone replacement for adrenal conditions may be permitted)
• People with a currently active autoimmune disease or a history of autoimmune disease
• People with certain lung conditions such as idiopathic pulmonary fibrosis, organising pneumonia, drug-related lung inflammation, or active pneumonia detected on a CT scan at screening
• People who have previously had a bone marrow or organ transplant from another person
• People with a known immune deficiency condition, whether present from birth or acquired (such as HIV infection)
• People with active hepatitis B or C infection (some people with hepatitis B who have been on antiviral therapy for at least 4 weeks and have a low viral level may still be eligible — confirm with the trial site)
• People who are known to be allergic to the study drug or any of its ingredients
• People who have received a live vaccine within 30 days before starting the trial, or who plan to receive one during treatment or within 90 days after the last dose
• People with a serious active infection within 2 weeks before starting the trial
• People who the investigator considers unsuitable for any other reason that could affect their safety or the reliability of the trial results

Important: Always verify eligibility with the trial site directly before applying.